MUNICH — Giving intensive statin therapy to patients with acute mild ischemic stroke or with high-risk for transient ischemic attack (TIA) immediately after onset significantly reduces the risk for a poor functional outcome compared with delaying treatment, without compromising safety, results of the INSPIRES trial show. The research, presented at the 9th European Stroke Organisation Conference (ESOC) on May 26, also […]
Ticagrelor May Reduce Brain Lesions After Carotid Stenting
MUNICH — Patients undergoing carotid artery stenting (CAS) may have fewer ischemic lesions and a lower lesion burden if they are given the reversible P2Y12 receptor antagonist ticagrelor rather than clopidogrel, another P2Y12 inhibitor, prior to the procedure, secondary endpoint results of the PRECISE-MRI trial suggest. More than 200 patients with carotid artery stenosis underwent magnetic resonance imaging (MRI) and were randomized […]
Cardiopathy No Basis for Choosing Anticoagulation in ESUS
MUNICH — Anticoagulation using apixaban (Eliquis) offers no benefit over aspirin in patients with embolic stroke of undetermined source (ESUS) who have atrial cardiopathy but no overt atrial fibrillation, suggest findings from the ARCADIA trial. The trial, which was halted early, randomized more than 1000 ESUS patients with atrial cardiomyopathy to apixaban or placebo. Results showed that apixaban did not improve […]
Post-Stroke Care Need to Improve Clinical Endpoints?
MUNICH — A multidisciplinary post-stroke care program failed to show a reduction in hard clinical endpoints over standard care after 1 year of follow-up, a new study shows, although it did achieve improvements in cardiovascular risk-related measures. Experts argued that the trial, presented at the European Stroke Organisation Conference (ESOC) 2023 on May 24, would […]